ALAMEDA, Calif.—(BUSINESS WIRE)—Advanced Cell Technology, Inc. (OTCBB:ACTC – News), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that it has retained Burrill & Company, a specialty merchant bank with expertise in biotechnology and related fields, to act as its financial advisor with regard to the formation of strategic partnerships designed to accelerate development of stem cell based cures and treatments.
Advanced Cell Technology is actively seeking corporate partners in regard to its proprietary technology and therapeutic development programs. Specifically, the Company plans to find development partners for its retinal, hemangioblast and dermal programs as it proceeds into human clinical trials.
Burrill & Company is a boutique merchant bank specializing in the life sciences industry that brings strong expertise in forming and optimizing strategic partnerships, especially in the international marketplace.
“We are excited to be working with the entire Burrill Team,” said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. “Burrill & Company brings a new level of expertise and focus to our corporate partnering efforts and I believe their firm will be instrumental in assisting us to fulfill our corporate partnering milestone.”
Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) with over $850 million under management.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
For more information, please visit: www.advancedcell.com.
For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/advanced_cell.
To read or download Advanced Cell’s Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/advanced_cell/factsheet.html.
To view recent stock quotes and news, visit http://www.trilogy-capital.com/tcp/advanced_cell/quote.html.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
The Investor Relations Group
Investors: James Carbonara, 212-825-3210
Media: Bill Douglass, 212-825-3210
or
Financial Communications
Trilogy Capital Partners
Paul Karon, 800-592-6067
Paul Karon
800-592-6067